Safety of Xeloda in Solid Tumours
NCT02479217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1268
Last updated 2017-02-17
Summary
The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.
Conditions
- Metastatic Breast Cancer, Colon Cancer
Interventions
- DRUG
- DRUG
-
Xeloda
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2009-06-30
- Completion
- 2009-06-30
Countries
- Serbia
Study Locations
More Related Trials
-
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
NCT00086528 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00415116 ·Status: COMPLETED ·Phase: PHASE1
-
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
NCT00413322 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
NCT00004057 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Mass Balance of the Test Drug and Major Metabolites
NCT00432302 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
NCT00975182 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
NCT01968915 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
NCT03050047 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
NCT03447470 ·Status: COMPLETED ·Phase: PHASE1
-
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT00379717 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
NCT03838926 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
NCT00704392 ·Status: WITHDRAWN ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00045448 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
NCT00502567 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
NCT00999401 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
NCT01148628 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
NCT00413075 ·Status: COMPLETED ·Phase: PHASE1
-
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
NCT03422679 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors
NCT01313598 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
NCT05525247 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
SB-743921 In Patients With Solid Tumors
NCT00136513 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862 ·Status: RECRUITING ·Phase: PHASE1
-
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
NCT03008018 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT01447225 ·Status: COMPLETED ·Phase: PHASE1
-
CHS 828 in Treating Patients With Solid Tumors
NCT00003979 ·Status: WITHDRAWN ·Phase: PHASE1